Hims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its ...

U.S. telehealth upstart Hims & Hers Health, Inc. is planning to enter the Canadian market with an eye to selling generic ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company eyes Canada expansion to offer affordable versions of Novo ...

Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors or individual stocks. Read more ...

Hims & Hers cofounder and CEO Andrew Dudum dropped out of Forbes’ billionaire ranks on Monday – less than two months after joining the three-comma-club, in May. Dudum, 36, lost more than $400 ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring ...

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a collaboration.

Investing.com -- Hims & Hers Health (NYSE: HIMS) stock rose 2% on Wednesday after the digital health platform announced plans to expand into Canada in 2026, coinciding with the anticipated first ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to partner with other Big Pharma names?